News 21.09.2020 Schlieren (Zurich), Switzerland, September 21, 2020 – Kuros Biosciences (SIX: KURN) today announced that over 2,000 patients have been treated worldwide with its MagnetOs bone graft, an alternative to the gold standard treatment of autograft. A substantial, and growing, number of clinically relevant and predictive animal studies have demonstrated the equivalence...
News 14.09.2020 Zurich-Schlieren, Switzerland, September 14, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the completion of initial Good Manufacturing Practice (GMP) manufacturing runs of its tri-specific, antiviral DARPin® candidate for COVID-19, named MP0420....
News 09.09.2020 Schlieren (Zurich), Switzerland, September 9, 2020 – Kuros Biosciences, a leader in next generation bone graft technologies, notes the successful initial public offering (IPO) on NASDAQ (NASDAQ: CMPI) of Checkmate Pharmaceuticals, which has licensed CMP-001, formerly known as CYT003, from Kuros. Checkmate raised gross proceeds of $75 million in its recent...
News 01.09.2020 Schlieren (Zurich), Switzerland, September 1, 2020 – Kuros Biosciences, a leader in next generation bone graft technologies, today announced that the first patient has been treated in the STRUCTURE trial, investigating Fibrin-PTH (KUR-113) for transforaminal lumbar interbody fusion (TLIF) procedures in patients with degenerative disc disease. The first patient was...
News 26.08.2020 Research & Development: Developed novel anti-COVID-19 multi-specific DARPin® candidates, of which MP0420 is being prepared for clinical trial initiation in Q4 2020. Initial in vitro and in vivo data highly supportive of unique mechanisms of action with ultra-potent anti-viral activity seen. Secured partnership with AGC Biologics to meet initial projected...